Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization†

We report herein the first systematic exploration of inhibitors of the mitotic kinase Nek2. Starting from HTS hit aminopyrazine 2, compounds with improved activity were identified using structure-based design. Our structural biology investigations reveal two notable observations. First, 2 and related compounds bind to an unusual, inactive conformation of the kinase which to the best of our knowledge has not been reported for other types of kinase inhibitors. Second, a phenylalanine residue at the center of the ATP pocket strongly affects the ability of the inhibitor to bind to the protein. The implications of these observations are discussed, and the work described here defines key features for potent and selective Nek2 inhibition, which will aid the identification of more advanced inhibitors of Nek2.

[1]  A. Fry,et al.  Nek2 kinase in chromosome instability and cancer. , 2006, Cancer letters.

[2]  A. Fry,et al.  APC/C‐mediated destruction of the centrosomal kinase Nek2A occurs in early mitosis and depends upon a cyclin A‐type D‐box , 2001, The EMBO journal.

[3]  F. Féru,et al.  Research Article: Selectivity‐determining Residues in Plk1 , 2007, Chemical biology & drug design.

[4]  Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists , 2005 .

[5]  R. Kellogg,et al.  Acid-catalyzed brominations, deuterations, rearrangements, and debrominations of thiophenes under mild conditions , 1968 .

[6]  J. Jackson,et al.  Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. , 2009, Bioorganic & medicinal chemistry letters.

[7]  D. Brautigan,et al.  Inhibitor-2 Regulates Protein Phosphatase-1 Complexed with NimA-related Kinase to Induce Centrosome Separation* , 2002, The Journal of Biological Chemistry.

[8]  M. Mahjoub,et al.  Caught Nek-ing: cilia and centrioles , 2005, Journal of Cell Science.

[9]  Matthieu Hamel,et al.  Journal of Medicinal Chemistry , 2010 .

[10]  A. Fürstner,et al.  Iron-catalyzed cross-coupling reactions. , 2002, Journal of the American Chemical Society.

[11]  M. Nagino,et al.  Nek2 as a novel molecular target for the treatment of breast carcinoma , 2009, Cancer science.

[12]  P. Meraldi,et al.  C-Nap 1 , a Novel Centrosomal Coiled-Coil Protein and Candidate Substrate of the Cell Cycle – regulated Protein Kinase Nek 2 , 1998 .

[13]  J. Senet,et al.  A new reagent for the selective, high-yield N-dealkylation of tertiary amines: improved syntheses of naltrexone and nalbuphine , 1984 .

[14]  J. Bartek,et al.  Substrate Specificity and Cell Cycle Regulation of the Nek2 Protein Kinase, a Potential Human Homolog of the Mitotic Regulator NIMA of Aspergillus nidulans(*) , 1995, The Journal of Biological Chemistry.

[15]  C. E. Allen,et al.  Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2. , 2010, Bioorganic & medicinal chemistry.

[16]  D. Riley,et al.  Phosphorylation of the Mitotic Regulator Protein Hec1 by Nek2 Kinase Is Essential for Faithful Chromosome Segregation* , 2002, The Journal of Biological Chemistry.

[17]  Wen-Hwa Lee,et al.  Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues. , 2009, Journal of medicinal chemistry.

[18]  M. R. Pillai,et al.  The Centrosomal Kinase Nek 2 Displays Elevated Levels of Protein Expression in Human Breast Cancer , 2004 .

[19]  P. Meraldi,et al.  A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators , 1998, The EMBO journal.

[20]  E. Casale,et al.  Through the "gatekeeper door": exploiting the active kinase conformation. , 2010, Journal of medicinal chemistry.

[21]  Susan S. Taylor,et al.  Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism , 2006, Proceedings of the National Academy of Sciences.

[22]  P. Chieffi,et al.  Phosphorylation of high-mobility group protein A2 by Nek2 kinase during the first meiotic division in mouse spermatocytes. , 2003, Molecular biology of the cell.

[23]  B. Narsaiah,et al.  A novel synthetic route to 2-amino-3-cyano-4-trifluoromethyl-6-substituted pyridines , 1994 .

[24]  A. Fry,et al.  Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. , 2003, Molecular biology of the cell.

[25]  R. Muschel,et al.  Inhibition of Centrosome Separation after DNA Damage: A Role for Nek2 , 2004, Radiation research.

[26]  M. Nagino,et al.  Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin , 2010, Cancer science.

[27]  Y. Martin,et al.  A bioavailability score. , 2005, Journal of medicinal chemistry.

[28]  P. Meraldi,et al.  C-Nap1, a Novel Centrosomal Coiled-Coil Protein and Candidate Substrate of the Cell Cycle–regulated Protein Kinase Nek2 , 1998, The Journal of cell biology.

[29]  A. Cheng,et al.  Structure of the catalytic domain of human polo-like kinase 1. , 2007, Biochemistry.

[30]  Andrew M. Fry,et al.  Coordinate Regulation of the Mother Centriole Component Nlp by Nek2 and Plk1 Protein Kinases , 2005, Molecular and Cellular Biology.

[31]  Mark W. Richards,et al.  Insights into the Conformational Variability and Regulation of Human Nek2 Kinase , 2009, Journal of molecular biology.

[32]  D. Riley,et al.  NIMA-Related Protein Kinase 1 Is Involved Early in the Ionizing Radiation-Induced DNA Damage Response , 2004, Cancer Research.

[33]  R. Bayliss,et al.  An Autoinhibitory Tyrosine Motif in the Cell-Cycle-Regulated Nek7 Kinase Is Released through Binding of Nek9 , 2009, Molecular cell.

[34]  M. Nagino,et al.  Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. , 2007, Cancer research.

[35]  Christopher J. Wilkinson,et al.  Rootletin forms centriole-associated filaments and functions in centrosome cohesion , 2005, The Journal of cell biology.

[36]  R. Snow,et al.  The synthesis of 5- and 6-substituted quinuclidine-3-carboxylic esters: intermediates for novel muscarinic ligands , 1991 .

[37]  P. Workman,et al.  Identification by High-Throughput Screening of Viridin Analogs as Biochemical and Cell-Based Inhibitors of the Cell Cycle–Regulated Nek2 Kinase , 2010, Journal of biomolecular screening.

[38]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[39]  James A. Marshall and,et al.  Synthesis of (-)-deoxypukalide, the enantiomer of a degradation product of the furanocembranolide pukalide. , 2001 .

[40]  Cheng-yi Chen,et al.  Cyclopropylboronic acid: synthesis and Suzuki cross-coupling reactions , 2002 .

[41]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[42]  Andrew M Fry,et al.  The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer , 2004, Cancer Research.